Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01508247
Other study ID # JSVCT010
Secondary ID
Status Completed
Phase Phase 3
First received January 4, 2012
Last updated March 27, 2013
Start date January 2012
Est. completion date March 2013

Study information

Verified date March 2013
Source Jiangsu Province Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Since its discovery in 1969, enterovirus 71 (EV71) has been recognised as a frequent cause of epidemics of hand-foot-mouth disease (HFMD) associated with severe neurological sequelae in a small proportion of cases. There has been a significant increase in EV71 epidemic activity throughout the Asia-Pacific region since 1997. Recent HFMD epidemics in this region have heen associated with a severe from of brainstem encephalitis associated with pulmonary oedema and high case-fatality rates.

The data from the phase 1 and 2 trials suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese children and infants. According to the immunogenicity and safety results, the 320U with adjuvant with immunizing schedule of two doses (per 28 day) will be applied in phase 3 clinical trial.


Recruitment information / eligibility

Status Completed
Enrollment 10245
Est. completion date March 2013
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender Both
Age group 6 Months to 35 Months
Eligibility Inclusion Criteria:

Only subjects fulfilling all of the following criteria will be eligible for the study:

- Healthy children aged from 6 to 35 months old

- General good health as established by medical history and physical examination

- The subjects' guardians are able to understand and sign the informed consent

- Had never received the vaccine against EV71

- The subjects' guardians allow to comply with the requirements of the protocol

- Available for all visits scheduled in this study

- Subjects with temperature <=37.0°C on axillary setting

Exclusion Criteria:

Subjects will not be eligible for the study if any of the following criteria is met:

- Subject who has a medical history of HFMD

- Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine

- Family history of seizures or progressive neurological disease

- Family history of congenital or hereditary immunodeficiency

- Severe malnutrition or hypogenesis

- Major congenital defects or serious chronic illness, including perinatal brain damage

- Autoimmune disease

- Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws

- Asplenia, functional asplenia, or splenic excision

- History of asthma, angioneurotic edema, diabetes or malignant tumour

- History of thyroidectomy, or thyroid disease in last 12 months

- Any acute infections in last 7 days

- Any prior administration of immunodepressant or corticosteroids in last 6 months

- Any prior administration of blood products in last 3 months

- Any prior administration of other research vaccines or medicines in last 1 month

- Any prior administration of attenuated live vaccine in last 15 days

- Any prior administration of subunit or inactivated vaccines in last 7 days

- Under the anti-TB prevention or therapy

- Subjects with temperature >37.0°C on axillary setting

- Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Exclusion Criteria for the second dose:

Subjects will not be eligible for the second dose if any of following adverse events happened after the first dose. They can continue other process of the study without the second dose vaccination according to the opinion of the investigator.

- Had any serious adverse events related to the first dose of inactivated vaccine (vero cell) against EV71 within 7 days

- Hypersensitivity reactions after vaccination (including urticaria/rashes that occur within 30 minutes after inoculation)

- Anaphylaxis after vaccination

- Any confirmed or suspected autoimmune disease or immune deficiency diseases, including human immunodeficiency virus (HIV) infection

- Any condition that in the opinion of the investigator, or IRB

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Intervention

Biological:
inactivated vaccine (Vero Cell) against EV71
inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
0/0.5ml placebo
0/0.5ml placebo, two doses, on day0, 28

Locations

Country Name City State
China Chaoyang Distinct Center for Disease Control and Prevention Beijing
China Donghai County Center for Disease Control and Prevention Lianyungang Jiangsu
China Pizhou County-Level City Center for Disease Control and Prevention Xuzhou Jiangsu
China Baoying County Center for Disease Control and Prevention Yangzhou Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Jiangsu Province Centers for Disease Control and Prevention Bejing Vigoo Biological Co., LTD

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the incidence density of the EV71-associated diseases in the vaccine group and placebo group. compare the incidence density of the EV71-associated diseases between the vaccine group and placebo group in Chinese children aged 6-35 months. begin at day 56 up to 14 months No
Secondary the frequency of all the adverse events in vaccine group and placebo group. compare frequency of all the solicited events, unsolicited adverse events and serious adverse events between vaccine group and placebo group. up to 14 months Yes
Secondary Seropositive rate of the vaccine group calculate the seropositive rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination. 8 months after first vaccination No
Secondary Seroconversion rate of the vaccine group calculate the seroconversion rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination. 8 months after first vaccination No
Secondary GMT of the vaccine group calculate the geometric mean titre (GMT) of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination. 8 months after first vaccination No
Secondary Seropositive rate of the vaccine group calculate the seropositive rate of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination. 14 months after first vaccination No
Secondary Seroconversion rate of the vaccine group calculate the seroconversion rate of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination. 14 months after first vaccination No
Secondary GMT of the vaccine group calculate the geometric mean titre (GMT) of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination. 14 months after first vaccination No
Secondary Seropositive rate of the vaccine group and placebo group compare the seropositive rate of the vaccine group and placebo group in healthy children aged 6-35 months. 28 days after the second vaccination No
Secondary Seroconversion rate of the vaccine group and placebo group compare the Seroconversion rate of the vaccine group and placebo group in healthy children aged 6-35 months. 28 days after the second vaccination No
Secondary GMT of the vaccine group and placebo group compare the geometric mean titre (GMT) of the vaccine group and placebo group in healthy children aged 6-35 months. 28 days after the second vaccination No
Secondary GMI of the vaccine group and placebo group compare the geometric mean fold increase (GMFI) of the vaccine group and placebo group in healthy children aged 6-35 months. 28 days after the second vaccination No
See also
  Status Clinical Trial Phase
Recruiting NCT06063057 - Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial Phase 1/Phase 2
Completed NCT04133584 - The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine Phase 4
Completed NCT03241030 - Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Phase 2
Completed NCT01255124 - Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children N/A
Completed NCT03873740 - Immunogenicity and Safety of Two Different Commercial EV71 Vaccines Phase 4
Completed NCT05637229 - A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia
Recruiting NCT06146088 - Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine Phase 4
Active, not recruiting NCT06209398 - Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine Phase 4
Recruiting NCT01175915 - A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Recruiting NCT01145664 - A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease N/A
Completed NCT01182532 - A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Completed NCT03281174 - Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine N/A
Completed NCT03582761 - Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71 Phase 4
Completed NCT03903926 - Efficacy Trial of a Commercial EV71 Vaccine Phase 4
Completed NCT02001233 - A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
Completed NCT03909074 - Clinical Trial of Enterovirus 71(EV71) Inactivated Vaccine in Children Aged 36-71 Months Phase 3
Completed NCT01769794 - Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study N/A
Recruiting NCT01182025 - A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Recruiting NCT06263439 - Surveillance of HFMD in Pediatric Outpatients
Not yet recruiting NCT05397587 - An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell) Phase 4